Technology | February 24, 2009

Digirad Corporation Features Latest in Volume CT (VCT) Attenuation Correction


Digirad's Cardius X-ACT, a dedicated cardiac SPECT system, offers the potential to set new clinical standards with X-ACT attenuation correction. The X-ACT system is based on the high-efficiency Cardius-3 XPO triple-head upright dedicated nuclear cardiac SPECT imaging system. The C3XPO offers up to 38 percent faster acquisition times than conventional dual head systems and the ability to image patients up to 500 pounds. The new X-ACT low dose volume CT (VCT) attenuation correction approach exploits the high-count rate capabilities of solid-state detectors and takes advantage of the full 24-inch-wide triple-head detector geometry eliminating truncation. X-ACT offers the potential benefits of high precision, faster speed, low dose and high reliability.

The X-ACT option is a clinical works-in-progress and is not available for commercial sale.


Related Content

News | SPECT-CT

September 12, 2022 — Royal Philips, a global leader in health technology, announced new milestones in the development of ...

Home September 12, 2022
Home
News | SPECT-CT

September 7, 2022 — The American Society of Nuclear Cardiology (ASNC) and three partner societies have come together to ...

Home September 07, 2022
Home
Technology | SPECT-CT

October 18, 2016 — At the 2016 annual meeting of the Radiological Society of North America (RSNA 2016), Siemens ...

Home October 18, 2016
Home
News | SPECT-CT

May 5, 2016 — Doctors and researchers at Barnes-Jewish Hospital and Washington University in St. Louis may be able to ...

Home May 05, 2016
Home
Subscribe Now